Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Mar 05, 2026
|
Vir Biotechnology Names CEO Marianne De Backer President
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
KOD
Kodiak Sciences Inc.
KSI-501 and KSI-101 are bispecific proteins, aligning with Bispecific Antibodies.
|
$1.42B |
$25.35
-5.55%
|
|
TNGX
Tango Therapeutics, Inc.
Directly develops oncology therapies (biotech) targeting genetically defined cancers, aligning with Biotech - Oncology.
|
$1.37B |
$15.81
+28.02%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$1.35B |
$71.43
+0.45%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$1.33B |
$9.21
-3.66%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$1.33B |
$16.02
-10.17%
|
|
DAWN
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals markets and develops Oral Small Molecule Therapeutics (OJEMDA/tovorafenib) as a lead product.
|
$1.32B |
$12.55
-2.49%
|
|
ORIC
ORIC Pharmaceuticals, Inc.
ORIC develops oncology therapies (e.g., ORIC-944, ORIC-114, ORIC-533) targeting cancer resistance, placing it in Biotech - Oncology.
|
$1.32B |
$13.49
-0.15%
|
|
SEPN
Septerna, Inc.
Septerna is focused on discovering and developing oral small molecule therapeutics targeting GPCRs (e.g., preclinical metabolic programs and GPCR targets under Novo Nordisk collaboration), which maps to the 'Oral Small Molecule Therapeutics' investable theme.
|
$1.29B |
$26.87
-6.78%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.27B |
$4.46
-3.99%
|
|
COLL
Collegium Pharmaceutical, Inc.
Jornay PM, Belbuca, Xtampza ER, and Nucynta are all oral small-molecule therapeutics, representing major product categories in Collegium's portfolio.
|
$1.25B |
$37.32
-5.78%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.25B |
$15.11
-7.07%
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Lead asset is an ophthalmic drug (DURAVYU) targeting wet AMD and DME.
|
$1.24B |
$15.70
-12.78%
|
|
IMTX
Immatics N.V.
Core product platform: TCR-engineered cell therapies (ACT) for solid tumors.
|
$1.24B |
$10.12
-0.54%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
NEO
NeoGenomics, Inc.
MRD-related diagnostics and companion diagnostics align with therapy selection and monitoring.
|
$1.18B |
$9.01
-1.04%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.17B |
$25.34
-0.65%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$1.17B |
$17.96
-0.99%
|
|
AZTA
Azenta, Inc.
Genewiz genomic sequencing and broader SMS/Multiomics services align with Contract Research Organizations.
|
$1.15B |
$24.69
-1.75%
|
|
GLUE
Monte Rosa Therapeutics, Inc.
GLUE develops oral small-molecule molecular glue degraders (MGDs) as its core therapeutic modality.
|
$1.15B |
$17.97
-3.44%
|
|
BHVN
Biohaven Ltd.
BHVN's Kv7 ion channel modulation platform (BHV-7000) and TRPM3 antagonist (BHV-2100) position the company in Ion Channel Modulators, a key neuroscience/pain modality.
|
$1.12B |
$10.28
-3.11%
|
|
PHAR
Pharming Group N.V.
Core rare-disease therapeutic developer focused on RUCONEST and an expanding rare-disease pipeline.
|
$1.10B |
$15.56
-4.07%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$1.10B |
$11.36
+1.88%
|
|
ZBIO
Zenas BioPharma, Inc.
Company focuses on immunology-based therapeutics for autoimmune diseases.
|
$1.09B |
$24.77
-4.07%
|
|
ABCL
AbCellera Biologics Inc.
AbCellera's primary product is its antibody discovery platform.
|
$1.09B |
$3.56
-1.79%
|
|
INBX
Inhibrx Biosciences, Inc.
Clinical-stage oncology biotech with DR5 and OX40 antibody programs.
|
$1.08B |
$70.22
-5.92%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$1.08B |
$24.63
-7.27%
|
|
RAPP
Rapport Therapeutics, Inc. Common Stock
Lead asset RAP-219 is a small molecule AMPAR NAM targeting neuronal ion channels, i.e., ion channel modulators.
|
$1.07B |
$28.93
-1.40%
|
|
PGEN
Precigen, Inc.
PRGN-2009 and other oncology programs position the company in Oncology biotech.
|
$1.06B |
$3.27
-8.03%
|
Showing page 8 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
